Tonix Cleared to Propel Migraine Therapy into Phase II

The Food and Drug Administration (FDA) has cleared the way for Tonix Pharmaceuticals to begin a Phase II study of its therapeutic candidate, which intends to prevent migraine headaches.

Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022. Tonix believes that TNX-1900, which works by stimulating oxytocin receptors in the trigeminal ganglia, can help migraine sufferers.